Roche's SERD Setback Means Menarini Retains An Edge

 
• By Jessica Merrill

Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.

horse race
Roche's SERD failed a Phase II trial in advanced breast cancer • Source: Alamy

More from Anticancer

More from Therapy Areas